SCHEMBL7148347

SCHEMBL7148347

CN(CC(=O)Nc1ccccc1)C(=O)[C@@H]1C[C@@H](S)CN1S(=O)(=O)c1ccc2ccccc2c1

nearest known ligand 0.75

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ECE1 P42892 7/20 0.75
MME P08473 2/20 0.75
ACE P12821 2/20 0.75
HCRTR1 O43613 1/20 0.43
HCRTR2 O43614 1/20 0.43
CCR4 P51679 3/20 0.43
PKM P14618 2/20 0.41
KDM4E B2RXH2 1/20 0.41
ALDH1A1 P00352 1/20 0.41
POLB P06746 1/20 0.41
BLM P54132 1/20 0.41
MAPT P10636 2/20 0.41
USP2 O75604 1/20 0.39
TP53 P04637 1/20 0.39
ALOX15 P16050 1/20 0.39
TSHR P16473 1/20 0.39
AKR1C3 P42330 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7146031 0.94 ECE1 (0.70) ECE1MMEACEHCRTR1HCRTR2
SCHEMBL7143562 0.94 ECE1 (0.70) ECE1MMEACEHCRTR1HCRTR2
SCHEMBL7148910 0.93 ECE1 (0.68) ECE1MMEACEHCRTR1HCRTR2
SCHEMBL7144738 0.93 ECE1 (0.68) ECE1MMEACEHCRTR1HCRTR2
SCHEMBL7144267 0.91 ECE1 (0.71) ECE1MMEACEHCRTR1HCRTR2
SCHEMBL7148854 0.89 ECE1 (0.85) ECE1MMEACEHCRTR1HCRTR2
SCHEMBL7141619 0.89 ECE1 (0.85) ECE1MMEACEHCRTR1HCRTR2
SCHEMBL7143279 0.89 MME (0.70) ECE1MMEACEALDH1A1MAPT
SCHEMBL7145879 0.89 MME (0.70) ECE1MMEACEALDH1A1MAPT
SCHEMBL7135136 0.89 MME (0.70) ECE1MMEACEALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6541638-B2 (2S,4S)-1-(4-Mercapto-1-(naphthalene-2-sulfonyl)-pyrrolidine-2 -carbonyl)-piperidine-4-carboxylic acid ethyl ester for example; zinc protease inhibitors; for treating diseases associated with vasoconstriction HOFFMAN-LA ROCHE INC. 2003-04-01 US disclosed
US-20020049243-A1 Pyrrolidine derivatives HOFFMANN-LA ROCHE INC. 2002-04-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020049243-A1 Pyrrolidine derivatives PREP, PEPD, DNPEP ECE1 4/4885MME 99/4885ACE 44/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.